New Marketing Authorisations for Aivlosin in China

RNS Number : 4879C

Eco Animal Health Group PLC

23 February 2022

 

23 February 2022

ECO Animal Health Group plc

("the Company" or the "Group")

(AIM: EAH)

ECO RECIEVES TWO NEW MARKETING AUTHORISATIONS FOR AIVLOSIN® IN CHINA

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited ("ECO") has received two marketing authorisations from the Ministry of Agriculture and Rural Affairs ("MOA") of the People's Republic of China for the use of Aivlosin® Water Soluble Granules ("WSG"). Aivlosin® is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

The first approval allows ECO to market Aivlosin® WSG in China for the treatment of respiratory disease caused by Mycoplasma and other sensitive bacteria in chickens laying eggs for human consumption and breeding chickens. Aivlosin® is the first antimicrobial to be licensed by the Chinese MOA for laying birds with a zero day drug withdrawal period for eggs.

The second Aivlosin® WSG approval is for swine respiratory disease ("SRD") adding three important bacterial respiratory pathogens of swine, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis to the existing Mycoplasma hyopneumoniae registration. SRD occurs worldwide and causes major economic losses to the pig industry due to mortality, reduction in growth rates and decreased feed efficiency.

Marc Loomes, CEO, commented: "We are delighted to receive these important marketing authorisations for Aivlosin® WSG. China is the world's largest producer of table eggs and accounts for more than a third of the world's laying birds. Aivlosin® is the first antimicrobial registered for use in laying hens producing eggs for human consumption, with a zero day egg withdrawal period.  This will enable ECO to target a new sector, the commercial egg producer, where Mycoplasmosis can cause significant economic losses.  China is also the largest pork producing country in the world and broader product label claims in the key SRD segment will serve our  business well as the market recovers in the future."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas	020 7496 3000
Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden	020 7418 8900
Investec (Joint Broker) Gary Clarence Alex Penney Carlo Spingardi	020 7597 5970
Equity Developments Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

END

 

 

MSCTTMLTMTTTBFT